News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
May 11, 2020Starting a new job … virtually
We speak to four of our newest team members about their experience of starting a job virtually.
May 04, 2020Compass Pathways Secures $80M Series B to Boost Depression Clinical Trial
Article in Crunchbase News provides an overview of Series A and B investment rounds. Featuring a comment from co-founder George Goldsmith, on what this means for COMPASS Pathways.
May 01, 2020Compass raises $80m for treatment-resistant depression drug based on magic mushrooms
Article in PM Live gives a brief overview of how the closing of second round funding will support research and trials involving psychedelic substances.
April 30, 2020Psychedelics Inc.
Article published on Medium giving an overview of startup companies developing treatments with psychedelic drugs. Featuring quotes from co-founder George Goldsmith.
April 30, 2020Compass raises $80M to take magic mushroom drug toward phase 3
Article published in FierceBiotech on the successful closing of our series B finding round, and preparation for phase 3 development. Featuring an interview with co-founder Lars Wilde.
April 28, 2020Mushroom magic draws $80M injection for London-based mental health startup
Endpoints article on our Series B funding round, including interview with our co-founder Lars Wilde.